Compare QSI & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QSI | MDWD |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.6M | 162.2M |
| IPO Year | 2020 | 2013 |
| Metric | QSI | MDWD |
|---|---|---|
| Price | $1.15 | $12.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.30 | ★ $30.67 |
| AVG Volume (30 Days) | ★ 9.2M | 78.8K |
| Earning Date | 11-05-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,436,000.00 | N/A |
| Revenue This Year | N/A | $39.60 |
| Revenue Next Year | $406.32 | $34.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $11.84 |
| 52 Week High | $2.44 | $19.70 |
| Indicator | QSI | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 41.90 |
| Support Level | $0.81 | N/A |
| Resistance Level | $1.32 | $14.06 |
| Average True Range (ATR) | 0.17 | 0.50 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 23.08 | 21.79 |
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.